

## OKMETIC INTERIM REPORT 1 JANUARY - 30 SEPTEMBER 2009

Okmetic is a technology company that supplies customised silicon wafers for the sensor and semiconductor industries and sells its technological expertise to the solar energy industry. During the period under review, the company's net sales amounted to 40.5 million euro (52.1 million euro). Loss for the period was -0.2 million euro (profit 6.9 million euro). Earnings per share were -0.01 euro (0.41 euro).

## KEY FIGURES

1,000 euro	1.7.- 30.9.09	1.7.- 30.9.08	1.1.- 30.9.09	1.1.- 30.9.08	1.1.- 31.12.08
Net sales	12,171	18,090	40,549	52,116	67,867
Operating profit before depreciation (EBITDA)	992	3,845	5,660	12,640	15,517
Operating profit/loss	-748	2,089	467	7,368	8,476
% of net sales	-6.1	11.5	1.2	14.1	12.5
Profit/loss for the period	-1,234	2,870	-168	6,942	5,825
Earnings per share, euro	-0.07	0.17	-0.01	0.41	0.34
Net cash flow from operating activities	192	4,522	4,457	10,299	13,177
Net interest-bearing liabilities	-2,914	1,807	-2,914	1,807	-586
Average number of personnel during the period	339	367	339	363	364

## REVIEW IN BRIEF

- New President for Okmetic. Antti Rasilo will leave the company today. Deputy to the president, Executive Vice President, Sales Mikko Montonen will handle the duties of President for the time being.
- The net sales in January-September 2009 amounted to 40.5 million euro (52.1 million euro) and in the third quarter to 12.2 million euro (18.1 million euro).
- Sales of sensor wafers in January-September are slightly lower than in 2008. Semiconductor wafer sales are still increasing after the low point in the first quarter. Sales in January-September are still clearly below last year's figures.
- Loss for the period was -0.2 million euro (profit 6.9 million euro). In the third quarter the loss for the period was -1.2 million euro (profit 2.9 million euro).
- The result was weighed down by the additional cost of 0.5 million euro caused by the outcome of the personnel negotiations conducted in September.
- As a result of the personnel negotiations the number of the clerical workers will be reduced by 22 persons and 23 manual workers will be temporarily laid off until further notice.
- Earnings per share were -0.01 euro (0.41 euro).
- The net cash flow from operations in January-September 2009 amounted to 4.5 million euro (10.3 million euro) and in the third quarter to 0.2 million euro (4.5 million euro).
- At the end of the period, the company's cash and cash equivalents exceeded the interest-bearing liabilities by 2.9 million euro (1.8 million euro lower).
- Net sales for the year 2009 are expected to amount to around 53 million euro. Operating profit is estimated to be slightly positive. Cash flow from operating activities is expected to be clearly positive.

## MARKETS

Customer industries

The global economic downturn has affected the market situation among Okmetic's customer industries in 2009. The sensor industry had grown accustomed to a steady market growth of above 10 percent a year. This year shipment volumes have increased more slowly than usual, though. Due to the market situation the prices have partially declined, too. In the first three quarters of the year, the sales of sensor products are estimated to be slightly below the corresponding period in 2008.

In semiconductor industry the beginning of the year was weak, but since then the industry has started to recover clearly. In the light of published sales figures, the gross invoicing for semiconductors quoted in US dollars fell in January-August by more than 20 percent year-on-year.

The solar panel market has clearly suffered from the general downturn and decreasing national subsidies in 2009. Stock volumes have increased and prices have fallen. Investments have slowed down due to increased caution amongst customers.

#### Silicon wafer industry

The increasing use of sensors in many consumer electronics applications has boosted the sensor market while the demand for wafers in the automotive industry has temporarily suffered. The difficult market situation of customer industries was also seen in the demand of semiconductor wafers. Semiconductor wafer deliveries in the first three quarters fell drastically compared to the corresponding period a year ago.

#### Okmetic

Okmetic's sales of sensor wafers have remained almost at the same level as a year ago, despite the market situation. Sales of semiconductor wafers have decreased significantly due to the general decline in demand. In a challenging market situation of 2009 Okmetic has succeeded to increase its market share in the main product areas.

#### PROJECTIONS FOR THE NEAR FUTURE

##### Customer industries

The market situation in the sensor industry is expected to remain stable the rest of the year. All-year sensor sales are expected to finish at about 10 percent below 2008 levels but to return to double-digit growth in 2010.

Semiconductor industry is in recovery. The forecasts for total sales in 2009 have recently been revised upwards, and the latest estimate is that the year-on-year drop in semiconductor invoicing will not reach 20 percent. Semiconductor sales are predicted to see a clear increase in 2010 and to return to the 2008 level.

Market growth in solar cells and panels is expected next year. Consequently, the technology sales market is expected to recover.

##### Silicon wafer industry

The market development of the silicon wafer industry is monitored in terms of surface area. According to a forecast published by SEMI (the global industry association of silicon wafer suppliers) in October, the total delivery volume in 2009 is projected to be around 6,300 million square inches. The volume is thus down about 20 percent from 2008. SEMI expects wafer demand to increase 23 percent in 2010.

#### Okmetic

Okmetic specialises in the manufacture of demanding sensor wafers and is the global market leader and a pioneer in technological development in this respect. The leading position as the supplier of advanced sensor wafers creates a sound basis for the company and substantial growth potential when the wafer industry is returning to a growth track. This is expected to happen next year. Okmetic's semiconductor wafer shipments have increased steadily since the low point

experienced in the first quarter of 2009. The increase in demand for semiconductor wafers is expected to continue in the last quarter of the year. Technology sales are expected to remain on level with Q3 figures in the fourth quarter. Due to the completion of the significant three-year technology sales project Okmetic is well positioned for signing new technology contracts.

Net sales for the year 2009 are expected to amount to around 53 million euro. Operating profit is estimated to be slightly positive. Cash flow from operating activities is expected to be clearly positive.

#### EVENTS AFTER THE INTERIM REPORT PERIOD

The company and President have mutually decided that Antti Rasilo, President since the beginning of 2003 leaves Okmetic today. Deputy to the president, Executive Vice President, Sales Mikko Montonen will handle the duties of President for the time being. The board of directors has initiated the search for a new President.

#### SALES

Okmetic's net sales in January-September 2009 decreased by 22.2 percent from the previous year (increased by 6.7%), amounting to 40.5 million euro (52.1 million euro). In the third quarter the net sales amounted to 12.2 million euro (18.0 million euro). Net sales went down, following especially the dramatic deterioration in the market situation of the semiconductor industry at the end of 2008 and the major three-year technology sales project which was nearly completed at the end of June 2009. Semiconductor wafers' market situation has improved from the first quarter continuously.

#### Net sales per customer area

	1.7.- 30.9.09	1.7.- 30.9.08	1.1.- 30.9.09	1.1.- 30.9.08	1.1.- 31.12.08
Sensor wafers	43%	38%	40%	36%	37%
Semiconductor wafers	38%	39%	27%	39%	38%
Technology	19%	23%	33%	25%	25%

Okmetic's sensor wafer sales in January-September 2009 remained slightly behind the previous year. The use of sensors is expected to continue its increase. Sensor applications are rapidly becoming more popular in cameras and other consumer electronics products, for example, in addition to the automotive industry and other traditional applications.

The falling share of semiconductor sales in our total sales is the result of the weak market situation. However, the market situation has improved continuously after the low point experienced in the first quarter of 2009. The most typical uses of semiconductor wafers include consumer electronics, information technology, telecommunications and the automotive industry.

Technology sales comprise not just manufacturing technology but also crystal sales and occasional polysilicon recycling. The fluctuations in sales volume percentages per customer area and market area are due to the nature of technology sales and irregular income recognition schedule.

#### Net sales per market area

	1.7.- 30.9.09	1.7.- 30.9.08	1.1.- 30.9.09	1.1.- 30.9.08	1.1.- 31.12.08
North America	38%	39%	36%	38%	39%
Europe	32%	25%	34%	34%	33%
Asia	30%	36%	30%	28%	28%

The exchange rates of the US dollar and Japanese yen against the euro have an effect on the way net sales are distributed between different market areas.

#### PROFITABILITY

Okmetic group's loss for the period was -0.2 million euro (profit 6.9 million euro) in January-September 2009. In the third quarter the loss for the period was -1.2 million euro (profit 2.9 million euro). Earnings per share were -0.01 euro (0.41 euro). The company's profits were burdened by the low operating rate resulting from the market situation in semiconductor wafers. Profits are also suffering as a result of the substantially lower recycling price received for silicon. Okmetic's result was weighed down by the additional cost of 0.5 million euro caused by the outcome of the personnel negotiations conducted in September as well as the exchange losses of 0.5 million euro in January-September. All the costs have been adjusted to the prevailing market situation in the group.

#### FINANCING AND INVESTMENTS

The group's financial situation is good. The company's cash and cash equivalents exceed the interest-bearing liabilities by 2.9 million euro (1.8 million euro lower). The net cash flow from operations in January-September 2009 amounted to 4.5 million euro (10.3 million euro) and in the third quarter to 0.2 million euro (4.5 million euro).

A total of 1.4 million euro was invested in refurbishing production equipment.

At the end of the period, cash and cash equivalents amounted to 17.3 million euro (17.5 million euro). Return on equity amounted to -0.5 percent (19.3%). The group's equity ratio was 66.6 percent (61.8%). Shareholders' equity per share amounted to 2.90 euro (2.98 euro).

#### PRODUCT DEVELOPMENT

The company invested 1.7 million euro (1.6 million euro) in long-term product development projects during the financial period. Product development accounted for 4.2 percent (3.2%) of the net sales. Okmetic engaged in several strategic research projects. R&D work focused on sensor wafers which are important to Okmetic.

#### PERSONNEL

On average, Okmetic employed 339 people (363). At the end of the period, 302 of the group's employees worked in Finland, 30 in the US and three in Japan. Majority of the company's personnel in Finland were temporarily laid off from one to six weeks in February-June 2009. As a result of the personnel negotiations conducted in September the number of the clerical workers will be reduced by 22 persons, of which 19 in Finland. 23 manual workers will be temporarily laid off until further notice in Finland. These actions will result in savings of over a million euro annually. The effect of the savings will be noticeable as of the beginning of 2010.

#### BUSINESS RISKS

Okmetic's silicon wafer sales are targeted at the sensor and semiconductor industries. The demand for semiconductor wafers is sensitive to economic fluctuations and changes in the market situation can be sudden and dramatic. The demand for sensor wafers is significantly more stable and sales of sensor wafers are developing favourably. The success of the sales strategy hinges on trouble-free contract manufacturing.

Okmetic's share of the global silicon wafer market is around one percent and the market prices have an effect on the price development of the company's products. The majority of sales are conducted in US dollars. The Japanese yen is another

notable trading currency. Despite hedging, the company remains exposed to exchange rate fluctuations.

Great volumes of electricity are used in Okmetic's production. The significant and long-term electricity hedging measures will have an impact on the result for the period if the price of electricity changes significantly.

#### SHARE PRICE DEVELOPMENT AND TRADING

A total of 2.9 million shares (7.1 million shares) were traded between 1 January and 30 September 2009, representing 17.1 percent (42.2%) of the share total of 16.9 million. The lowest quotation of the period was 1.81 euro (2.20 euro) and the highest was 2.99 euro per share (3.14 euro), with an average of 2.40 euro (2.66 euro). The closing quotation for the period was 2.67 euro (3.00 euro). The total market value of the share capital amounted to 45.1 million euro at the end of the financial period (50.7 million euro).

#### OWN SHARES

The company has not redeemed its own shares.

#### AUTHORISATION OF THE BOARD OF DIRECTORS TO DECIDE ON REPURCHASING THE COMPANY'S OWN SHARES

The extraordinary general meeting held on 6 November 2008 authorised the board of directors to decide on repurchasing the company's own shares as follows. The aggregate number of shares repurchased on the basis of the authorisation cannot exceed 1,688,750 shares, which represents 10 percent of all the shares of the company.

Only unrestricted shareholders' equity can be used to repurchase the company's own shares under the authorisation. Own shares can be repurchased at a price determined by public trading on the day of repurchase or at another market-based price. The authorisation will remain in force until the annual general meeting of spring 2010, although in any case not past 6 May 2010.

#### AUTHORISATION OF THE BOARD OF DIRECTORS TO DECIDE ON TRANSFERRING RIGHTS TO THE COMPANY'S OWN SHARES

The extraordinary general meeting held on 6 November 2008 authorised the board of directors to decide on transferring rights to the company's own shares as follows. The aggregate number of rights transferred on the basis of the authorisation cannot exceed 1,688,750 shares, which represents 10 percent of all the shares of the company. The authorisation will remain in force until further notice, although in any case not past 30 June 2013.

#### AUTHORITY OF THE BOARD OF DIRECTORS TO INCREASE SHARE CAPITAL

The annual general meeting held on 2 April 2009 authorised the board of directors to decide on increasing the company's share capital. The aggregate number of shares issued on the basis of the authorisation cannot exceed 3,377,500 shares, which represents approximately 20 percent of all the shares of the company.

The board of directors was authorised to decide on all the terms and conditions concerning the issue of shares and other share entitlements. The authorisation relates to the issuance of new shares. Issuance of shares and other share entitlements can be carried out as a directed issue. The authorisation is effective until the following annual general meeting.

The board has not taken advantage of the authorisations by 30 September 2009.

## CONVERTIBLE BONDS AND OPTION PROGRAMMES

Okmetic has no convertible bonds or option programmes at the moment.

## CONDENSED FINANCIAL STATEMENTS AND TABLES 1 JANUARY - 30 SEPTEMBER 2009 (unaudited)

These interim financial statements have been prepared in accordance with IAS 34 standard.

In preparing these interim financial statements, Okmetic has followed the same accounting policies as in the financial statements for 2008 except that the company has adopted the following new or revised standards as of 1 January 2009:

- IAS 1, Presentation of Financial Statements - amendment
- IFRS 8, Operating Segments

The amendment to IAS 1 affects the way the income statement and the statement of changes in equity are presented. The amendment to IFRS 8 does not affect the information presented for segments, because the segment data provided by the group have always been based on the group's internal reporting structure.

## CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

1,000 euro	1.7.- 30.9.09	1.7.- 30.9.08	1.1.- 30.9.09	1.1.- 30.9.08	1.1.- 31.12.08
Net sales	12,171	18,090	40,549	52,116	67,867
Cost of sales	-10,906	-13,627	-35,281	-39,141	-50,687
Gross profit	1,264	4,463	5,268	12,974	17,180
Other income and expenses	-2,012	-2,374	-4,801	-5,606	-8,704
Operating profit/loss	-748	2,089	467	7,368	8,476
Financial income and expenses	-509	595	-861	-468	-2,900
Profit/loss before tax	-1,257	2,683	-394	6,900	5,576
Income tax	23	186	225	42	248
Profit/loss for the period	-1,234	2,870	-168	6,942	5,825
Other comprehensive income:					
Translation differences	-190	628	-293	364	560
Available-for-sale financial assets	-	-281	-	-900	114
Other comprehensive income for the period, net of tax	-190	347	-293	-536	674
Total comprehensive income for the period	-1,425	3,217	-462	6,406	6,499
Profit/loss for the period attributable to:					
Equity holders of the parent company	-1,234	2,870	-168	6,942	5,825
Total comprehensive income attributable to:					
Equity holders of the parent company	-1,425	3,217	-462	6,406	6,499
Basic and diluted earnings per share, euro	-0.07	0.17	-0.01	0.41	0.34

# CONDENSED CONSOLIDATED BALANCE SHEET

1,000 euro	Sept 30, 2009	Sept 30, 2008	Dec 31, 2008
Assets			
Non-current assets			
Property, plant and equipment	34,830	40,163	38,848
Available-for-sale financial assets	-	1,541	-
Other receivables	4,361	5,388	4,619
Total non-current assets	39,191	47,092	43,468
Current assets			
Inventories	7,494	7,617	10,753
Receivables	9,836	10,105	9,289
Cash and cash equivalents	17,259	17,493	17,975
Total current assets	34,588	35,215	38,016
Total assets	73,778	82,307	81,484
Equity and liabilities			
Equity			
Equity attributable to equity holders of the parent company			
Share capital	11,821	11,821	11,821
Other equity	37,192	38,475	38,568
Total equity	49,013	50,296	50,389
Liabilities			
Non-current liabilities	12,538	15,504	14,027
Current liabilities	12,228	16,506	17,068
Total liabilities	24,766	32,010	31,095
Total equity and liabilities	73,778	82,307	81,484

# CONDENSED CONSOLIDATED CASH FLOW STATEMENT

1,000 euro	Jan 1- Sept 30, 2009	Jan 1- Sept 30, 2008	Jan 1- Dec 31, 2008
Cash flows from operating activities:			
Profit/loss before tax	-394	6,900	5,576
Adjustments	5,864	5,678	11,272
Change in working capital	-607	-1,902	-2,935
Interest received	239	322	424
Interest paid and other financial items	-644	-674	-1,135
Tax paid	-	-24	-26
Net cash from operating activities	4,457	10,299	13,177
Cash flows from investing activities:			
Proceeds from investing activities	641	21	469
Capital expenditure	-1,666	-1,482	-2,646
Net cash used in investing activities	-1,025	-1,461	-2,177
Cash flows from financing activities:			

Repayments of long-term borrowings	-3,023	-2,873	-4,748
Payments of finance lease liabilities	-96	-161	-198
Dividends paid	-844	-1,689	-1,689
Net cash used in financing activities	-3,964	-4,723	-6,634
Increase (+) / decrease (-) in cash and cash equivalents	-532	4,115	4,365
Exchange rate changes	-184	70	301
Cash and cash equivalents at the beginning of the period	17,975	13,308	13,308
Cash and cash equivalents at the end of the period	17,259	17,493	17,975

#### CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

1,000 euro	Equity attributable to equity holders of parent company					
	Share capital	Share premium	Trans-lation diffe- rences	Fair value reserve	Retained earnings	Total equity
Balance at 31 Dec 2008	11,821	20,115	635	-	17,818	50,389
Total comprehensive income for the period			-293		-168	-462
Dividend distribution					-844	-844
Equity component of convertible loan notes		-70				-70
Balance at 30 Sept 2009	11,821	20,045	341	-	16,805	49,013
Balance at 31 Dec 2007	11,821	20,186	75	-114	13,682	45,649
Total comprehensive income for the period			364	-900	6,942	6,406
Dividend distribution					-1,689	-1,689
Equity component of convertible loan notes		-70				-70
Balance at 30 Sept 2008	11,821	20,115	438	-1,013	18,935	50,296

#### CHANGES IN PROPERTY, PLANT AND EQUIPMENT

1,000 euro	Jan 1- Sept 30, 2009	Jan 1- Sept 30, 2008	Jan 1- Dec 31, 2008
Carrying amount at the beginning of the period	38,848	43,355	43,355
Additions	1,440	1,948	2,773
Disposals	-	-	-537
Depreciation	-5,193	-5,272	-7,041



Exchange differences	-265	133	298
Carrying amount at the end of the period	34,830	40,163	38,848

#### CHANGES IN FINANCIAL LIABILITIES

1,000 euro	Jan 1- Sept 30, 2009	Jan 1- Sept 30, 2008	Jan 1- Dec 31, 2008
Carrying amount at the beginning of the period	17,389	22,259	22,259
Proceeds of loans from financial institutions	-	-	999
Repayments of loans from financial institutions	-2,020	-1,870	-4,744
Repayments of subordinated loans	-928	-928	-928
Changes in finance lease liabilities	-96	-161	-198
Carrying amount at the end of the period	14,345	19,300	17,389

#### DIVIDENDS PAID

In April, the company distributed a dividend of 0.8 million euro of the profit accrued in 2008, representing a 0.05 euro dividend per share.

#### COMMITMENTS AND CONTINGENCIES

1,000 euro	Sept 30, 2009	Sept 30, 2008	Dec 31, 2008
Loans secured with collaterals	12,167	14,500	13,333
Collaterals	24,964	29,001	24,964
Off-balance sheet lease commitments	109	260	165
Capital commitments	110	-	574
Nominal values of derivative contracts			
Currency forward agreements	-	1,344	-
Currency options, call	-	689	-
Currency options, put	-	345	-
Electricity derivatives	2,544	2,609	2,961
Interest rate swaps	7,071	-	-
Fair values of derivative contracts			
Currency forward agreements	-	-49	-
Currency options, call	-	15	-
Currency options, put	-	-11	-
Electricity derivatives	-646	522	-540
Interest rate swaps	-64	-	-

The contract price of the derivatives has been used as the nominal value of the underlying asset. Derivative contracts are for hedging.

#### RELATED PARTY TRANSACTIONS

Key management compensation during the period under review amounted to 895,000 euro (1,152,000 euro).

# KEY FIGURES SHOWING FINANCIAL PERFORMANCE

1,000 euro	Jan 1- Sept 30, 2009	Jan 1- Sept 30, 2008	Jan 1- Dec 31, 2008
Net sales	40,549	52,116	67,867
Change in net sales compared to the previous year's period, %	-22.2	6.7	5.0
Export and foreign operations share of net sales, %	95.6	95.4	95.6
Operating profit before depreciation (EBITDA)	5,660	12,640	15,517
% of net sales	14.0	24.3	22.9
Operating profit	467	7,368	8,476
% of net sales	1.2	14.1	12.5
Profit/loss before tax	-394	6,900	5,576
% of net sales	-1.0	13.2	8.2
Return on equity, %	-0.5	19.3	12.1
Return on investment, %	0.3	15.5	9.9
Non-interest-bearing liabilities	10,421	12,710	13,707
Net interest-bearing liabilities	-2,914	1,807	-586
Net gearing ratio, %	-5.9	3.6	-1.2
Equity ratio, %	66.6	61.8	62.8
Capital expenditure	1,440	1,948	2,773
% of net sales	3.6	3.7	4.1
Depreciation	5,193	5,272	7,041
Research and development expenditure 1)	1,714	1,645	2,261
% of net sales	4.2	3.2	3.3
Average number of personnel during the period	339	363	364
Personnel at the end of the period	335	361	363

1) Research and development expenditure has been presented in gross figures and only long-term projects based on research program have been taken into account.

# KEY FIGURES PER SHARE

Euro	Sept 30, 2009	Sept 30, 2008	Dec 31, 2008
Earnings per share basic and diluted	-0.01	0.41	0.34
Equity per share	2.90	2.98	2.98
Dividend per share	-	-	0.05
Dividends/earnings, %	-	-	14.5
Effective dividend yield, %	-	-	2.1
Price/earnings (P/E)	-267.6	7.3	7.0
Share price performance(Jan 1-)			
Average trading price	2.40	2.65	2.63
Lowest trading price	1.81	2.20	2.15
Highest trading price	2.99	3.14	3.14
Trading price at the end of the period	2.67	3.00	2.40
Market capitalisation at the end of the period, 1,000 euro	45,090	50,663	40,530
Trading volume (Jan 1-)			
Trading volume, transactions	2,895,265	7,129,877	8,355,374
In relation to weighted average number of shares, %	17.1	42.2	49.5
Trading volume, euro	6,938,955	18,877,311	22,002,739

The weighted average number of shares during the period under review				
adjusted by the share issue	16,887,500	16,887,500	16,887,500	16,887,500
The number of shares at the end of the period adjusted by the share issue	16,887,500	16,887,500	16,887,500	16,887,500

#### QUARTERLY KEY FIGURES

	10-12/09	7-9/09	4-6/09	1-3/09
Net sales		12,171	13,538	14,841
Compared to previous quarter %		-10.1	-8.8	-5.8
Operating profit/loss		-748	688	527
% of net sales		-6.1	5.1	3.6
Profit/loss before tax		-1,257	46	818
% of net sales		-10.3	0.3	5.5
Net cash flow generated from:				
Operating activities		192	4,761	-496
Investing activities		-87	-786	-152
Financing activities		-22	-3,905	-37
Increase/decrease in cash and cash equivalents		83	70	-685
Personnel at the end of the period		335	343	338
	10-12/08	7-9/08	4-6/08	1-3/08
Net sales	15,751	18,090	16,992	17,034
Compared to previous quarter %	-12.9	6.5	-0.2	7.9
Operating profit	1,108	2,089	2,737	2,542
% of net sales	7.0	11.5	16.1	14.9
Profit/loss before tax	-1,323	2,683	2,582	1,634
% of net sales	-8.4	14.8	15.2	9.6
Net cash flow generated from:				
Operating activities	2,878	4,522	3,495	2,281
Investing activities	-716	-289	-841	-331
Financing activities	-1,912	-48	-4,616	-58
Increase/decrease in cash and cash equivalents	250	4,185	-1,962	1,892
Personnel at the end of the period	363	361	370	359

## DEFINITIONS OF KEY FINANCIAL FIGURES

Operating profit before depreciation (EBITDA)	=	Operating profit + depreciation
Return on equity, % (ROE)	=	$\frac{\text{Profit/loss for the period from continuing operations} \times 100}{\text{Equity (average for the period)}}$
Return on investment, % (ROI)	=	$\frac{(\text{Profit/loss before tax} + \text{interest and other financial expenses}) \times 100}{\text{Balance sheet total} - \text{non-interest bearing liabilities (average for the period)}}$
Equity ratio, %	=	$\frac{\text{Equity} \times 100}{\text{Balance sheet total} - \text{advances received}}$
Net gearing ratio, %	=	$\frac{(\text{Interest-bearing liabilities} - \text{cash and cash equivalents}) \times 100}{\text{Equity}}$
Earnings per share	=	$\frac{\text{Profit/loss for the period attributable to the equity holders of the parent company}}{\text{Adjusted weighted average number of shares in issue during the period}}$
Equity per share	=	$\frac{\text{Equity attributable to the equity holders of the parent company}}{\text{Adjusted number of shares at the end of the period}}$
Dividend per share	=	$\frac{\text{Dividend for the period}}{\text{Adjusted number of shares at the end of the period}}$
Effective dividend yield, %	=	$\frac{\text{Dividend per share} \times 100}{\text{Trading price at the end of the period}}$
Price/earnings ratio (P/E)	=	$\frac{\text{Last adjusted trading price at the end of the period}}{\text{Earnings per share}}$
Average trading price	=	$\frac{\text{Total traded amount in euro}}{\text{Adjusted number of shares traded during the period}}$
Market capitalisation at the end of the period	=	Number of shares at the end of the period x trading price at the end of the period
Trading volume	=	$\frac{\text{Number of shares traded during the period}}{\text{Weighted average number of shares during the period}}$

All figures of the financial tables are rounded, and consequently the sum of individual figures can deviate from the presented sum figure.

The figures are unaudited. In the written report, the figures in parenthesis refer to the corresponding period in the previous year.

The future estimates and forecasts in this interim report bulletin are based on company management's current knowledge. Actual events and results may differ from the estimates presented here.

OKMETIC OYJ

Board of directors

PRESS CONFERENCE

Okmetic will hold a press conference for the media and analysts on Friday 30 October 2009 at 9.00 a.m at the World Trade Center, Aleksanterinkatu 17, second floor, Helsinki.

For further information, please contact:

Chairman of the board, Henri Österlund, Okmetic Oyj,  
tel. + 358 50 348 9600

Deputy to the president, Mikko Montonen, Okmetic Oyj  
tel. + 358 40 5011 262, email: mikko.montonen@okmetic.com

Senior Vice President, Finance Esko Sipilä, Okmetic Oyj,  
tel. +358 9 5028 0286, email: esko.sipila@okmetic.com

Distribution:

NASDAQ OMX Helsinki  
Principal media  
[www.okmetic.com](http://www.okmetic.com)

OKMETIC IN BRIEF

Take it higher

Okmetic is a technology company which supplies tailor-made silicon wafers for sensor and semiconductor industries and sells its technological expertise to the solar energy industry. Okmetic provides its customers with solutions that boost their competitiveness and profitability.

Okmetic's silicon wafers are part of a further processing chain that produces end products that improve human interaction and quality of life. Okmetic's products are based on high-tech expertise that generates added value for customers, innovative product development and an extremely efficient production process.

Okmetic has a global customer base and sales network, production plants in Finland and the US and contract manufacturers in Japan and China.

Okmetic's shares are listed on NASDAQ OMX Helsinki under the code OKM1V. For more information on the company, please visit our website at [www.okmetic.com](http://www.okmetic.com).